We are live on
!
Find out more
CC
Casdin Capital Portfolio holdings
AUM
$2B
1-Year Est. Return
147.21%
This Fund
S&P 500
This Quarter
Est. Return
-6.36%
1 Year Est. Return
+147.21%
3 Year Est. Return
+369.71%
5 Year Est. Return
+164.99%
10 Year Est. Return
+6,568.53%
AUM
$1.32B
AUM Growth
-$289M
(-18%)
Cap. Flow
-$25.4M
Cap. Flow
% of AUM
-1.92%
Top 10 Holdings %
Top 10 Hldgs %
77.26%
Holding
47
New
9
Increased
7
Reduced
4
Closed
7
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGMB
AgomAb Therapeutics NV
AGMB
|
+$22M |
| 2 |
GRAL
GRAIL Inc
GRAL
|
+$17.8M |
| 3 |
10x Genomics
TXG
|
+$17.5M |
| 4 |
Qiagen
QGEN
|
+$17M |
| 5 |
Personalis
PSNL
|
+$13.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
RNAM
Avidity Biosciences
RNAM
|
+$72.1M |
| 2 |
ARS Pharmaceuticals
SPRY
|
+$18.6M |
| 3 |
UnitedHealth
UNH
|
+$16.5M |
| 4 |
DexCom
DXCM
|
+$11.6M |
| 5 |
Cigna
CI
|
+$11M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Veracyte
VCYT
$3.48B
| $8.9M | 0.67% |
276,308
| – | – |
|
27
MoonLake Immunotherapeutics
MLTX
$1.28B
| $8.39M | 0.64% |
+450,000
| New | +$7.45M |
|
28
Intellia Therapeutics
NTLA
$1.8B
| $4.55M | 0.34% |
+355,000
| New | +$4.52M |
|
29
Disc Medicine
IRON
$3.07B
| $4.16M | 0.31% |
+65,000
| New | +$4.51M |
|
30
Moderna
MRNA
$55.1B
| $3.81M | 0.29% |
+75,000
| New | +$3.5M |
|
|
ANL
31
Adlai Nortye Group ADS
ANL
$890M
| $3.73M | 0.28% |
+538,461
| New | +$3.6M |
|
32
Monte Rosa Therapeutics
GLUE
$1.14B
| $3.06M | 0.23% |
186,014
+100,000
| +116% | +$1.91M |
|
33
Absci
ABSI
$1.49B
| $2.92M | 0.22% |
973,260
| – | – |
|
34
Century Therapeutics
IPSC
$366M
| $2.78M | 0.21% |
1,228,190
| – | – |
|
|
BBOT
35
BridgeBio Oncology
BBOT
$701M
| $2.53M | 0.19% |
282,312
| – | – |
|
|
CTNM
36
Contineum Therapeutics
CTNM
$641M
| $1.94M | 0.15% |
148,333
| – | – |
|
37
Pacific Biosciences
PACB
$435M
| $955K | 0.07% |
723,767
-3,500,000
| -83% | -$6.26M |
|
38
Recursion Pharmaceuticals
RXRX
$1.79B
| $508K | 0.04% |
165,323
| – | – |
|
39
Tenaya Therapeutics
TNYA
$155M
| $251K | 0.02% |
361,969
| – | – |
|
40
Ginkgo Bioworks
DNA
$469M
| $224K | 0.02% |
36,493
| – | – |
|
|
41
Cigna
CI
$73.7B
| – | – |
-40,000
| Closed | -$11M |
|
|
42
DexCom
DXCM
$34.3B
| – | – |
-175,000
| Closed | -$11.6M |
|
43
Incyte
INCY
$25.2B
| – | – |
-100,000
| Closed | -$9.88M |
|
44
Legend Biotech
LEGN
$3.87B
| – | – |
-215,000
| Closed | -$4.67M |
|
|
RNAM
45
DELISTED
Avidity Biosciences
RNAM
| – | – |
-1,000,000
| Closed | -$72.1M |
|
|
46
ARS Pharmaceuticals
SPRY
$586M
| – | – |
-1,600,000
| Closed | -$18.6M |
|
|
47
UnitedHealth
UNH
$353B
| – | – |
-50,000
| Closed | -$16.5M |
|
Similar funds
KOCAA
NL
CAM
SB
BGGS
CC
JWA
FOF
Casdin Capital's Q1 2026 Portfolio in Review
As of Q1 2026, Casdin Capital held 47 positions worth $1.32B, down 18% from $1.61B the previous quarter. Its ten largest holdings account for 77% of the portfolio.
Casdin Capital's Q1 2026 filing shows 9 new, 7 increased, 4 reduced and 7 closed positions. Its largest new stake was AgomAb Therapeutics NV: 1,550,000 shares worth $16.3M. The largest sale was Avidity Biosciences, an estimated $72.1M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
- Casdin Capital's largest Q1 2026 buy was AgomAb Therapeutics NV: 1,550,000 shares worth $16.3M.
- Casdin Capital added most to 10x Genomics in Q1 2026, an estimated $17.5M increase.
- Casdin Capital's biggest Q1 2026 reduction was Illumina, cutting an estimated $9.19M.
- Casdin Capital fully exited Avidity Biosciences in Q1 2026, selling an estimated $72.1M.
- Casdin Capital's ten largest holdings make up 77% of its $1.32B portfolio in Q1 2026.
- Casdin Capital opened 9 new positions and closed 7 in Q1 2026.
- Casdin Capital's portfolio value fell 18% quarter-over-quarter to $1.32B.
Based on Casdin Capital's 13F filing for Q1 2026, filed 15 May 2026.